marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-14-2024
Protalix BioTherapeutics Balance Sheet 2011-2024 | PLX
Annual Balance Sheet Protalix BioTherapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-17.6 M | 12.2 M | -9.89 M | - | 37.5 M | 10.2 M | 1.02 M | 14.2 M | -4.28 M | 12.7 M | -19.4 M | -52 M | -27 M |
Long Term Debt |
4.62 M | 28.2 M | 27.9 M | - | 51 M | 48 M | 46.3 M | 23.6 M | 72.1 M | 67.5 M | 67 M | - | - |
Long Term Debt Current |
1.41 M | 1.12 M | 1.21 M | 1.42 M | 1.14 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
5.34 M | 34 M | 46.5 M | 8.5 M | 75.5 M | 88.7 M | 80.8 M | 26 M | 75.1 M | 108 M | 114 M | 56.3 M | 59.2 M |
Total Current Liabilities |
45.5 M | 32.4 M | 33.2 M | 86.5 M | 40.2 M | 25.4 M | 22.8 M | 66.2 M | 11.2 M | 26.2 M | 26.7 M | 25.8 M | 18.7 M |
Total Liabilities |
50.9 M | 66.4 M | 79.7 M | 95 M | 116 M | 114 M | 104 M | 92.2 M | 86.4 M | 134 M | 140 M | 82.1 M | 77.9 M |
Deferred Revenue |
- | 13.2 M | 8.55 M | 5.39 M | 16.3 M | 9.87 M | - | 837 K | 504 K | 6.76 M | 9.37 M | 9.44 M | 6.12 M |
Retained Earnings |
-382 M | -390 M | -375 M | -347 M | -341 M | -323 M | -298 M | -213 M | -183 M | -241 M | -211 M | -184 M | -172 M |
Total Assets |
84.4 M | 55.8 M | 73.7 M | 67.9 M | 45.4 M | 61.1 M | 72.2 M | 82.2 M | 97.3 M | 78.5 M | 113 M | 78.7 M | 51.8 M |
Cash and Cash Equivalents |
23.6 M | 17.1 M | 39 M | 18.3 M | 17.8 M | 37.8 M | 51.2 M | 63.3 M | 76.4 M | 54.8 M | 86.4 M | 52 M | 27 M |
Book Value |
33.6 M | -10.6 M | -6.04 M | -27 M | -70.3 M | -52.9 M | -31.3 M | -9.96 M | 10.9 M | -55.6 M | -26.9 M | -3.36 M | -26.1 M |
Total Shareholders Equity |
33.6 M | -10.6 M | -6.04 M | -27 M | -70.3 M | -52.9 M | -29.5 M | -9.96 M | 10.9 M | -55.6 M | -26.9 M | -3.36 M | -26.1 M |
All numbers in USD currency
Quarterly Balance Sheet Protalix BioTherapeutics
| 2024-Q3 | 2024-Q2 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
4.18 M | 4.28 M | 4.5 M | 20.1 M | 28.3 M | 28.2 M | 28.1 M | 28 M | 28 M | 27.9 M | 27.8 M | 4.51 M | 4.32 M | 4.47 M | 53.5 M | 52.6 M | 51.8 M | 51 M | 51 M | 51 M | 51 M | 48 M | 48 M | 48 M | 48 M | 46.3 M | 46.3 M | 46.3 M | 46.3 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 67.8 M | 67.8 M | 67.8 M | 67.8 M | 912 K | 67.5 M | 912 K | 912 K | 2.37 M | 2.37 M | 2.37 M | 2.37 M | 5.42 M | 5.42 M | 5.42 M | 5.42 M | 6.57 M | 6.57 M | 6.57 M | - |
Total Non Current Liabilities |
4.91 M | 4.99 M | 5.96 M | 26.3 M | 34 M | 34 M | 33.9 M | 39.6 M | 40.5 M | 46.5 M | 40.5 M | 8.12 M | 7.43 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 75.5 M | 75.5 M | 75.5 M | 75.5 M | 88.7 M | 88.7 M | 88.7 M | 88.7 M | 78.9 M | 78.9 M | 78.9 M | 78.9 M | 26 M | 26 M | 26 M | 26 M | 75.1 M | 75.1 M | 75.1 M | 75.1 M | 69.6 M | 108 M | 108 M | 108 M | 114 M | 114 M | 114 M | 114 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 59.2 M | 59.2 M | 59.2 M | 59.2 M |
Total Liabilities |
29.1 M | 63 M | 49.3 M | 49.4 M | 65.6 M | 66.4 M | 68.2 M | 70.5 M | 75.9 M | 79.7 M | 83.3 M | 104 M | 88.3 M | 95 M | 95 M | 95 M | 95 M | 116 M | 116 M | 116 M | 116 M | 114 M | 114 M | 114 M | 114 M | 102 M | 102 M | 102 M | 102 M | 92.2 M | 92.2 M | 92.2 M | 92.2 M | 86.4 M | 86.4 M | 86.4 M | 86.4 M | 134 M | 134 M | 134 M | 134 M | 140 M | 140 M | 140 M | 140 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M | 77.9 M | 77.9 M | 77.9 M | 77.9 M |
Deferred Revenue |
- | 12.7 M | - | - | 11.8 M | 13.2 M | 14.8 M | 10.2 M | 11.8 M | 8.55 M | 15.2 M | 18.1 M | 2.56 M | 5.39 M | 5.39 M | 5.39 M | 5.39 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 9.87 M | 9.87 M | 9.87 M | 9.87 M | - | - | 1.92 M | 1.92 M | 837 K | 837 K | 837 K | 837 K | 504 K | 504 K | 504 K | 504 K | 886 K | 6.76 M | 6.76 M | 6.76 M | 9.37 M | 9.37 M | 9.37 M | 9.37 M | 9.44 M | 9.44 M | 9.44 M | 9.44 M | 6.12 M | 6.12 M | 6.12 M | 6.12 M |
Retained Earnings |
- | - | - | - | - | - | - | - | - | -375 M | - | - | - | -347 M | - | - | - | -341 M | 341 M | 338 M | - | -323 M | - | - | - | -296 M | -296 M | -296 M | -296 M | -213 M | - | - | - | -183 M | - | - | - | -241 M | - | - | - | -211 M | - | - | - | -184 M | - | - | - | -172 M | - | - | - |
Total Assets |
61.6 M | 91.5 M | 87.6 M | 88.4 M | 66.6 M | 55.8 M | 56.7 M | 60.6 M | 68.4 M | 73.7 M | 83.5 M | 108 M | 103 M | 67.9 M | 67.9 M | 67.9 M | 67.9 M | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 61.1 M | 61.1 M | 61.1 M | 61.1 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 97.3 M | 97.3 M | 97.3 M | 97.3 M | 78.4 M | 78.5 M | 78.5 M | 78.5 M | 113 M | 113 M | 113 M | 113 M | 78.7 M | 78.7 M | 78.7 M | 78.7 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M |
Cash and Cash Equivalents |
27.4 M | 23.4 M | 20.4 M | 48.2 M | 33 M | 17.1 M | 10.7 M | 12.5 M | 16.9 M | 39 M | 10.6 M | 33.9 M | 19.8 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 51.2 M | 51.2 M | 51.2 M | 51.2 M | 63.3 M | 63.3 M | 63.3 M | 63.3 M | 76.4 M | 76.4 M | 76.4 M | 76.4 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 86.4 M | 86.4 M | 86.4 M | 86.4 M | 52 M | 52 M | 52 M | 52 M | 27 M | 27 M | 27 M | 27 M |
Book Value |
32.4 M | 28.6 M | 38.2 M | 39 M | 1.01 M | -10.6 M | -11.5 M | -9.89 M | -7.49 M | -6.04 M | 213 K | 3.84 M | 14.5 M | -27 M | -27 M | -27 M | -27 M | -70.3 M | -70.3 M | -70.3 M | -70.3 M | -52.9 M | -52.9 M | -52.9 M | -52.9 M | -29.5 M | -29.5 M | -29.5 M | -29.5 M | -9.96 M | -9.96 M | -9.96 M | -9.96 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | -55.6 M | -55.6 M | -55.6 M | -55.6 M | -26.9 M | -26.9 M | -26.9 M | -26.9 M | -3.36 M | -3.36 M | -3.36 M | -3.36 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M |
Total Shareholders Equity |
32.4 M | 28.6 M | 38.2 M | 39 M | 1.01 M | -10.6 M | -11.5 M | -9.89 M | -7.49 M | -6.04 M | 213 K | 3.84 M | 14.5 M | -27 M | -27 M | -27 M | -27 M | -70.3 M | -70.3 M | -70.3 M | -70.3 M | -52.9 M | -52.9 M | -52.9 M | -52.9 M | -29.5 M | -29.5 M | -29.5 M | -29.5 M | -9.96 M | -9.96 M | -9.96 M | -9.96 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | -55.6 M | -55.6 M | -55.6 M | -55.6 M | -26.9 M | -26.9 M | -26.9 M | -26.9 M | -3.36 M | -3.36 M | -3.36 M | -3.36 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M |
All numbers in USD currency